Clinicopathological analysis of nine consecutive central nervous system primitive neuroectodermal tumors in a single institute

详细信息    查看全文

• 作者：Misaki Aizawa-Kohama (1)
  Toshihiro Kumabe (1)
  Ryuta Saito (1)
  Masayuki Kanamori (1)
  Yoji Yamashita (1)
  Yukihiko Sonoda (1)
  Mika Watanabe (2)
  Teiji Tominaga (1)
  
• 关键词：Central nervous system primitive neuroectodermal tumor ; Ependymoblastoma ; Histopathology ; Neuroblastoma ; Treatment
• 刊名：Brain Tumor Pathology
• 出版年：2013
• 出版时间：January 2013
• 年：2013
• 卷：30
• 期：1
• 页码：15-27
• 全文大小：1749KB
• 参考文献：1. Rorke LB (1983) The cerebellar medulloblastoma and its relationship to primitive neuroectodermal tumors. J Neuropathol Exp Neurol 42:1-5 CrossRef
  2. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2007) WHO classification of tumours of the central nervous system. WHO Press, Geneva, pp 141-46
  3. Dirks PB, Harris L, Hoffman HJ, Humphreys RP, Drake JM, Rutka JT (1996) Supratentorial primitive neuroectodermal tumors in children. J Neurooncol 29:75-4 CrossRef
  4. Kuhl J, Muller HL, Berthold F et al (1998) Preradiation chemotherapy of children and young adults with malignant brain tumors: results of the German pilot trial HIT-8/-9. Klin Padiatr 210:227-33 CrossRef
  5. Timmermann B, Kortmann RD, Kuhl J et al (2002) Role of radiotherapy in the treatment of supratentorial primitive neuroectodermal tumors in childhood: results of the prospective German brain tumor trials HIT 88/89 and 91. J Clin Oncol 20:842-49 CrossRef
  6. Pizer BL, Weston CL, Robinson KJ et al (2006) Analysis of patients with supratentorial primitive neuro-ectodermal tumours entered into the SIOP/UKCCSG PNET 3 study. Eur J Cancer 42:1120-128 CrossRef
  7. Yasuda K, Taguchi H, Sawamura Y et al (2008) Low-dose craniospinal irradiation and ifosfamide, cisplatin and etoposide for non-metastatic embryonal tumors in the central nervous system. Jpn J Clin Oncol 38:486-92 CrossRef
  8. Kanamori M, Kumabe T, Saito R, Yamashita Y, Sonoda Y, Tominaga T (2010) The safety of combination chemotherapy with ifosfamide, cisplatin, and etoposide (ICE): single-institution retrospective review of 108 cases. No Shinkei Geka 38:997-005
  9. Chintagumpala M, Hassall T, Palmer S et al (2009) A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET. Neurooncology 11:33-0
  10. McBride SM, Daganzo SM, Banerjee A et al (2008) Radiation is an important component of multimodality therapy for pediatric non-pineal supratentorial primitive neuroectodermal tumors. Int J Radiat Oncol Biol Phys 72(5):1319-323 CrossRef
  11. Szekessy DP, Stoltenburg-Didinger G (2001) Differentiation, proliferation and apoptosis in primary and recurrent primitive neuroectodermal tumors of childhood. Childs Nerv Syst 17:320-27 CrossRef
  12. Janss AJ, Yachnis AT, Silber JH et al (1996) Glial differentiation predicts poor clinical outcome in primitive neuroectodermal brain tumors. Ann Neurol 39:481-89 CrossRef
  13. Jaros E, Perry RH, Adam L et al (1992) Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. Br J Cancer 66:373-85 CrossRef
  14. Woodburn RT, Azzarelli B, Montebello JF, Goss IE (2001) Intense p53 staining is a valuable prognostic indicator for poor prognosis in medulloblastoma/central nervous system primitive neuroectodermal tumors. J Neurooncol 52:57-2 CrossRef
  15. Sonoda Y, Yokosawa M, Saito R et al (2010) O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma. Int J Clin Oncol 15:352-58 CrossRef
  
• 作者单位：Misaki Aizawa-Kohama (1)
  Toshihiro Kumabe (1)
  Ryuta Saito (1)
  Masayuki Kanamori (1)
  Yoji Yamashita (1)
  Yukihiko Sonoda (1)
  Mika Watanabe (2)
  Teiji Tominaga (1)
  
  1. Department of Neurosurgery, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan
  2. Department of Pathology, Tohoku University Hospital, Sendai, Miyagi, Japan
  
• ISSN：1861-387X

文摘

The objective of this study was to determine the outcome of central nervous system primitive neuroectodermal tumors (CNS PNETs) and to clarify the histopathological findings as prognostic factors. We performed a retrospective analysis of nine consecutive patients with CNS PNETs who underwent treatment at our institute between 1993 and 2011. All patients were treated by surgical resection followed by chemoradiotherapy. Additional treatment, including surgical resection, was performed at relapse. Expression of immunohistochemical markers was examined for neuronal, astrocytic, mesenchymal, and epithelial differentiation, and also for TP53, O6-methylguanine-DNA methyltransferase, and Ki-67. Five-year progression-free survival was 18.2?% and the overall survival was 52.5?%. Five the 9 patients had recurrence and 4 patients died during the median follow-up period of 41.1?months. All 4 patients died of dissemination not local recurrence. After relapses, the extent of differentiation was different in each case and TP53 changed to positive or negative, but the Ki-67 labeling index did not reveal any differences between primary and recurrent tumors. A treatment procedure to prevent and treat dissemination of CNS PNETs should be established. Because the pathological change after relapse was different in each case, definitive histopathological prognostic factors for CNS PNETs are still difficult to propose.